Core Viewpoint - Shanghai has introduced measures to promote the high-quality development of commercial health insurance, aiming to enhance insurance services for public health and support the innovation of the biopharmaceutical industry [1] Group 1: Policy Measures - The measures consist of 5 areas and 18 specific actions designed to improve the accessibility and affordability of innovative drugs and medical devices [1] - There is an emphasis on deepening the payment mechanism for innovative drugs and medical devices, facilitating their entry into hospitals, directories, and prescriptions [1] - Innovative drug applications within the scope of commercial health insurance will not be included in the disease-based payment range, encouraging insurance companies to use clinical trial data for pricing [1] Group 2: Integration of Insurance Systems - Shanghai plans to enhance the functionality of the "Shanghai Insurance Code" to optimize the synchronous settlement model between medical insurance and commercial insurance [1] - Improvements will be made to direct compensation service processes, creating a proactive compensation system that integrates medical, health insurance, and commercial insurance data [1] - The goal is to achieve a unified compensation system, referred to as "one code for compensation" [1] Group 3: Impact on Public Health - The introduction of these measures is expected to position commercial health insurance as a crucial pillar in the public health security system [1] - The measures aim to provide the public with more comprehensive, diverse, and convenient health protection [1]
上海出台18条措施促生物医药创新 满足市民群众多层次健康保障需求
Ren Min Ri Bao·2025-08-07 22:45